- Current report filing (8-K)
07 Dezembro 2009 - 11:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 7,
2009 (December 5, 2009)
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 8 Other Events
Item 8.01 Other
Events.
On December 5, 2009,
Allos Therapeutics, Inc. (the Company) issued a press release announcing
new analyses of data from the Companys pivotal PROPEL trial of FOLOTYN
TM
(pralatrexate
injection) in patients with relapsed or refractory peripheral T-cell lymphoma
(PTCL). The Company also reported
preliminary results from its Phase 1/2 study of FOLOTYN in combination with
gemcitabine in patients with relapsed or refractory lymphoproliferative
malignancies and certain other data presented during poster sessions at the 51
st
Annual
Meeting of the American Society of Hematology (ASH) in New Orleans, LA. The press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1
|
|
Press Release, dated December 5, 2009, entitled Allos Therapeutics Reports New Analyses
from Pivotal PROPEL Trial of FOLOTYN
TM
at 51
st
ASH Annual Meeting.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: December 7, 2009
|
|
|
|
|
|
|
|
|
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H.
Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice
President, General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated December 5, 2009, entitled Allos Therapeutics Reports New Analyses
from Pivotal PROPEL Trial of FOLOTYN
TM
at 51
st
ASH Annual Meeting.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024